ArticleIET systems biology
Decoding Asthma Therapy: The Role of VEGFA and HIF1A in Yanghe Pingchuan Granule's Mechanism.
Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study integrated network pharmacology, bioinformatics, and experimental validation to investigate the glycolysis-related targets of Yanghe Pingchuan granule (YPG) in asthma therapy. Active ingredients of YPG were screened via TCMSP, with targets identified through UniProt. Asthma-associated differentially expressed genes (DEGs) were extracted from GEO datasets, whereas asthma- and glycolysis-related targets were mined from GeneCards, OMIM, TTD, DrugBank and MSigDB. Venn analysis identified three key genes (GSTP1, VEGFA and HIF1A) linked to HIF-1 and VEGF signalling pathways. Molecular docking confirmed strong binding between core YPG compounds (quercetin, kaempferol and luteolin) and these targets. ROC analysis demonstrated high diagnostic value of VEGFA and HIF1A for asthma. In vivo validation showed that YPG significantly downregulated GSTP1, VEGFA and HIF1A expression in asthmatic rats. Our findings establish VEGFA and HIF1A as pivotal glycolysis-associated targets in asthma, indicating that YPG exerts anti-asthma effects by modulating these critical regulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.